Living with or caring for someone with Hemophilia A can bring unique challenges. You may know that Hemophilia A is a bleeding disorder related to Factor VIII, a protein needed for blood clotting. But did you know that the specific genetic change causing the condition can significantly influence how severe it is and how it's best treated? Understanding the role of genetics provides powerful insights for managing Hemophilia A and looking toward the future.
What is Hemophilia A?
Hemophilia A is a rare, inherited bleeding disorder. It's caused by a problem with the gene that makes Factor VIII, a crucial clotting protein. This gene, called F8, is located on the X chromosome. Because men have only one X chromosome, they are primarily affected by Hemophilia A. Women have two X chromosomes, so even if one has a faulty F8 gene, the other can often compensate, making them carriers who may or may not have bleeding symptoms (Berntorp et al., 2021; Pezeshkpoor & Oldenburg, 2022).
People with Hemophilia A have reduced levels or activity of Factor VIII. This makes it harder for their blood to clot properly, leading to prolonged bleeding episodes, either spontaneously or after injury or surgery (Chowdary et al., 2025). In the past, this significantly impacted life expectancy, but thanks to improved diagnosis and treatment, individuals with hemophilia can now anticipate a near-normal life span and quality of life (Berntorp et al., 2021; Bolton-Maggs & Pasi, 2003).
The F8 Gene and Its Instructions
Think of the F8 gene as a recipe book for making Factor VIII. The gene contains the instructions, and your body uses these instructions to build the protein. In Hemophilia A, there's a mistake, or "mutation," in this recipe book. This mistake can cause the body to make:
- No Factor VIII at all
- A reduced amount of Factor VIII
- Factor VIII that doesn't work correctly
The type of mistake in the F8 gene determines how much functional Factor VIII is present in the blood, which directly impacts the severity of Hemophilia A (Berntorp etorp et al., 2021; Pezeshkpoor & Oldenburg, 2022).
How Gene Mutations Influence Hemophilia A Severity
The severity of Hemophilia A is classified based on the level of Factor VIII activity in the blood:
- Severe Hemophilia A: Less than 1% Factor VIII activity. Often results in frequent spontaneous bleeding, especially into joints and muscles.
- Moderate Hemophilia A: 1% to 5% Factor VIII activity. Bleeding is less frequent and may occur after minor injuries.
- Mild Hemophilia A: 6% to 40% Factor VIII activity. Bleeding usually only occurs after significant injury, surgery, or trauma (Chowdary et al., 2025).
The specific type of mutation in the F8 gene dictates where a person falls on this spectrum. Researchers have identified over 3,500 different pathogenic variants in the F8 gene (Pshenichnikova et al., 2023). These mutations aren't all the same; they can be:
- Large Inversions: Mistakes where a large piece of the gene is flipped around, like the common intron 22 inversion or intron 1 inversion. These often lead to severe Hemophilia A (Pshenichnikova et al., 2023; Mosaad et al., 2021).
- Large Deletions: Sections of the gene are missing. These are also frequently associated with severe disease (Pshenichnikova et al., 2023).
- Nonsense Mutations: A mistake that tells the cell to stop making the protein too early, resulting in a non-functional or missing protein. Can lead to severe Hemophilia A (Mosaad et al., 2021).
- Missense Mutations: A single change in the gene's code that results in the wrong "building block" (amino acid) being used in the protein. This can lead to a protein that doesn't work as well. The impact varies widely; some missense mutations cause severe hemophilia, while others result in moderate or mild forms (Pshenichnikova et al., 2023; Lopes et al., 2021).
- Small Deletions/Insertions or Splice-Site Mutations: Small changes that can disrupt the gene's message in various ways, leading to different severity levels (Pshenichnikova et al., 2023).
Understanding the specific mutation helps predict the likely severity of the condition, though other genetic factors might also play a role (Lopes et al., 2021).
The Power of Genetic Testing
Genetic testing for Hemophilia A involves analyzing a person's F8 gene to identify the specific mutation. This testing is crucial for several reasons:
- Accurate Diagnosis: Confirms the diagnosis of Hemophilia A and distinguishes it from other bleeding disorders (Pezeshkpoor & Oldenburg, 2022; Pruthi, 2005).
- Predicting Severity: Knowing the specific mutation can help predict the likely severity level, aiding in early planning and management (Berntorp et al., 2021).
- Genetic Counseling: Provides essential information for patients and their families about the inheritance pattern, risks to other family members, and family planning options (Pezeshkpoor & Oldenburg, 2022; Pruthi, 2005).
- Carrier Identification: Accurately identifies female carriers in a family, who may be at risk of bleeding themselves or passing the mutation to their children (Maher & Bergstrom, 2025; Bui et al., 2022).
- Family Planning: Allows for options like preimplantation genetic testing (PGT-M) to test embryos before implantation, preventing the transmission of the known mutation to the next generation (Bui et al., 2022).
Genetic analysis has advanced significantly, making it possible to identify the causative variants in most patients (Pezeshkpoor & Oldenburg, 2022).
Genetic Profile and Personalized Treatment
Knowing a patient's specific genetic mutation provides valuable information that can help guide treatment decisions, leading to more effective and personalized care plans.
One major challenge in Hemophilia A treatment is the potential development of inhibitors. These are antibodies that the body's immune system makes against the infused Factor VIII treatment, rendering it less effective or ineffective (Berntorp et al., 2021; Bolton-Maggs & Pasi, 2003). The risk of developing inhibitors is significantly influenced by the type of F8 gene mutation. For example, studies have shown that patients with large deletions or nonsense mutations have a higher risk of inhibitor development compared to those with intron 22 inversions or missense mutations (Gouw et al., 2012). Understanding this risk based on the genetic profile allows healthcare providers to monitor patients more closely and plan treatment strategies accordingly.
Genetic insights also play a role in the rapidly evolving landscape of Hemophilia A therapies. New treatments, such as non-factor therapies and gene therapy, are becoming available (Chowdary et al., 2025; Hart et al., 2019). Gene therapy, for instance, aims to deliver a functional copy of the F8 gene to the patient's cells, allowing their body to produce Factor VIII internally (Leavitt et al., 2024; Ay et al., 2024). The success and suitability of these advanced therapies can be influenced by the patient's underlying genetic makeup, including the specific F8 mutation and potentially other genetic factors that influence the immune response or how treatments are processed by the body (Cao et al., 2009; Hart et al., 2019).
While research into genetic variability across different populations is ongoing, initial studies, such as genetic analysis in Egyptian patients identifying specific mutations correlating with severity, highlight that genetic profiles can vary among different groups, potentially influencing how the disease presents and responds to treatment (Mosaad et al., 2021).
The Future of Hemophilia A Care
The connection between genetic mutations and Hemophilia A severity and treatment response is a cornerstone of modern hemophilia care. As genetic research continues to advance, we gain deeper insights into the complex relationship between the F8 gene, Factor VIII protein function, and clinical outcomes. This knowledge is driving the development of highly personalized treatment approaches, from optimizing traditional factor replacement therapy based on individual needs to developing targeted gene therapies.
Genetic testing is no longer just for diagnosis; it's a vital tool for predicting, planning, and personalizing care throughout a person's life. By understanding the unique genetic blueprint of Hemophilia A in each individual, healthcare teams can work towards minimizing bleeding episodes, preventing complications like inhibitors, and improving overall quality of life. The future of Hemophilia A management is increasingly rooted in the power of genetics, offering hope for more effective and tailored therapies.
References
Andersson, N. G., Labarque, V., Letelier, A., Mancuso, M. E., Bührlen, M., Fischer, K., Kartal-Kaess, M., Koskenvuo, M., Mikkelsen, T., Ljung, R., & PedNet study group. (2020). Novel F8 and F9 gene variants from the PedNet hemophilia registry classified according to ACMG/AMP guidelines. Haemophilia, 26(6), 1079-1086. doi: 10.1111/hae.14067
Ay, C., Frenzel, L., Pinachyan, K., & Le Quellec, S. (2024). Gene therapy for haemophilia A and B, from basic principles to clinical implementation: An illustrated review. Haemophilia, 30(2), e248-e261. doi: 10.1111/hae.14935
Berntorp, E., Fischer, K., Hart, D. P., Mancuso, M. E., Stephensen, D., Shapiro, A. D., & Blanchette, V. (2021). Haemophilia. The Lancet, 397(10280), 1482-1493. doi: 10.1016/S0140-6736(21)00474-0
Bolton-Maggs, P. H. B., & Pasi, K. J. (2003). Haemophilias A and B. The Lancet, 361(9371), 1813-1821. doi: 10.1016/S0140-6736(03)13401-5
Bui, T. M. P., Tran, V. K., Nguyen, T. T. H., Le, T. P., Nguyen, T. M., Tran, H. A., Luu, V. D., Nguyen, M. H., Bui, T.-H., Ta, T. V., & Tran, T. H. (2022). Preimplantation genetic testing (PGT) for hemophilia A: Experience from one center. Molecular Therapy. Methods & Clinical Development, 26, 275-281. doi: 10.1016/j.omtm.2022.06.008
Cao, O., Hoffman, B. E., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Ertl, H. C. J., High, K. A., & Herzog, R. W. (2009). Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Blood, 113(21), 5119-5127. doi: 10.1182/blood-2009-01-200185
Chowdary, P., Carcao, M., Kenet, G., & Pipe, S. W. (2025). Haemophilia. The Lancet, 405(10473), 148-162. doi: 10.1016/S0140-6736(24)02313-2
Gouw, S. C., van den Berg, H. M., Oldenburg, J., Astermark, J., de Groot, P. G., Margaglione, M., Thompson, A. R., van Heerde, W., Boekhorst, J., Miller, C. H., le Cessie, S., & van der Bom, J. G. (2012). F8 gene mutation type and inhibitor development in patients with severe hemophilia A: Systematic review and meta-analysis. Blood, 119(13), 2985-2994. doi: 10.1182/blood-2011-09-379468
Hart, D. P., Kessler, C. M., & Aledort, L. (2019). Re-personalization and stratification of hemophilia care in an evolving treatment landscape. Haemophilia, 25(6), 893-899. doi: 10.1111/hae.13862
Leavitt, A. D., Konkle, B. A., Stine, K. C., Visweshwar, N., Harrington, T. J., Giermasz, A., Arkin, S., Fang, A., Plonski, F., Yver, A., Ganne, F., Agathon, D., Resa, M. de L. A., Tseng, L.-J., Di Russo, G., Cockroft, B. M., Cao, L., & Rupon, J. (2024). Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study. Blood Advances, 8(1), 205-214. doi: 10.1182/bloodadvances.2023010574
Lopes, T. J. S., Rios, R., Nogueira, T., & Mello, R. F. (2021). Prediction of hemophilia A severity using a small-input machine-learning framework. Scientific Reports, 11(1), 16530. doi: 10.1038/s41598-021-95994-y
Maher, K. N., & Bergstrom, K. (2025). Genetic testing for children at risk to be hemophilia carriers. Pediatric Blood & Cancer, 72(1), e31258. doi: 10.1002/pbc.31258
Mosaad, R. M., Amr, K. S., Rabie, E. A., Mostafa, N. O., Habib, S. A., & El-Kamah, G. Y. (2021). Genomic alterations in the F8 gene correlating with severe hemophilia A in Egyptian patients. Molecular Genetics & Genomic Medicine, 9(11), e1810. doi: 10.1002/mgg3.1810
Pezeshkpoor, B., & Oldenburg, J. (2022). Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice. Genes, 13(12), 2339. doi: 10.3390/genes13122339
Pshenichnikova, O., Salomashkina, V., Poznyakova, J., Selivanova, D., Chernetskaya, D., Yakovleva, E., Dimitrieva, O., Likhacheva, E., Perina, F., Zozulya, N., & Surin, V. (2023). Spectrum of Causative Mutations in Patients with Hemophilia A in Russia. Biomedicines, 11(10), 2712. doi: 10.3390/biomedicines11102712
Pruthi, R. K. (2005). Hemophilia: a practical approach to genetic testing. Mayo Clinic Proceedings, 80(11), 1485-1499. doi: 10.4065/80.11.1485